The beta emitters [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T are currently the most frequently used therapeutic PSMA tracers in prostate cancer, but have not been compared head-to-head 18, 20. This evidence concerns the gene FOLH1 and prostate carcinoma.